Logo image of SEPN

SEPTERNA INC (SEPN) Stock Fundamental Analysis

NASDAQ:SEPN - Nasdaq - US81734D1046 - Common Stock - Currency: USD

7.48  +0.34 (+4.76%)

After market: 7.85 +0.37 (+4.95%)

Fundamental Rating

3

Taking everything into account, SEPN scores 3 out of 10 in our fundamental rating. SEPN was compared to 198 industry peers in the Pharmaceuticals industry. While SEPN has a great health rating, there are worries on its profitability. While showing a medium growth rate, SEPN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SEPN has reported negative net income.
SEPN had a negative operating cash flow in the past year.
SEPN Yearly Net Income VS EBIT VS OCF VS FCFSEPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.73%, SEPN is in the better half of the industry, outperforming 65.66% of the companies in the same industry.
SEPN has a Return On Equity of -17.09%. This is in the better half of the industry: SEPN outperforms 72.22% of its industry peers.
Industry RankSector Rank
ROA -15.73%
ROE -17.09%
ROIC N/A
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEPN Yearly ROA, ROE, ROICSEPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

SEPN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEPN Yearly Profit, Operating, Gross MarginsSEPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SEPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SEPN has been increased compared to 1 year ago.
SEPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SEPN Yearly Shares OutstandingSEPN Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
SEPN Yearly Total Debt VS Total AssetsSEPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 5.17 indicates that SEPN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.17, SEPN belongs to the top of the industry, outperforming 82.83% of the companies in the same industry.
SEPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.17
ROIC/WACCN/A
WACC9.64%
SEPN Yearly LT Debt VS Equity VS FCFSEPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 27.77 indicates that SEPN has no problem at all paying its short term obligations.
SEPN has a Current ratio of 27.77. This is amongst the best in the industry. SEPN outperforms 97.98% of its industry peers.
A Quick Ratio of 27.77 indicates that SEPN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 27.77, SEPN belongs to the best of the industry, outperforming 97.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 27.77
Quick Ratio 27.77
SEPN Yearly Current Assets VS Current LiabilitesSEPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SEPN have decreased strongly by -53868.89% in the last year.
The Revenue has grown by 611.92% in the past year. This is a very strong growth!
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.27%
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.66%

3.2 Future

SEPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.57% yearly.
Based on estimates for the next years, SEPN will show a very strong growth in Revenue. The Revenue will grow by 161.69% on average per year.
EPS Next Y75.79%
EPS Next 2Y29.37%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue Next Year-49.82%
Revenue Next 2Y-41.42%
Revenue Next 3Y161.69%
Revenue Next 5YN/A

3.3 Evolution

SEPN Yearly Revenue VS EstimatesSEPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2M 4M 6M 8M 10M
SEPN Yearly EPS VS EstimatesSEPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SEPN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SEPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEPN Price Earnings VS Forward Price EarningsSEPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEPN Per share dataSEPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as SEPN's earnings are expected to grow with 17.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.37%
EPS Next 3Y17.57%

More info and screens

0

5. Dividend

5.1 Amount

SEPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEPTERNA INC

NASDAQ:SEPN (5/2/2025, 8:22:52 PM)

After market: 7.85 +0.37 (+4.95%)

7.48

+0.34 (+4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners111.8%
Inst Owner Change-0.01%
Ins Owners3.41%
Ins Owner Change22.85%
Market Cap329.87M
Analysts80
Price Target15.81 (111.36%)
Short Float %8.27%
Short Ratio5.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-39.61%
PT rev (3m)-64.5%
EPS NQ rev (1m)11.39%
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.71%
EPS NY rev (3m)26.52%
Revenue NQ rev (1m)-25%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.94%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 309.22
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-7.26
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0.02
BVpS9.45
TBVpS9.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.73%
ROE -17.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.11%
Cap/Sales 195.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.77
Quick Ratio 27.77
Altman-Z 5.17
F-Score4
WACC9.64%
ROIC/WACCN/A
Cap/Depr(3y)237.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.27%
EPS Next Y75.79%
EPS Next 2Y29.37%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.66%
Revenue Next Year-49.82%
Revenue Next 2Y-41.42%
Revenue Next 3Y161.69%
Revenue Next 5YN/A
EBIT growth 1Y-77.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.58%
EBIT Next 3Y-42.59%
EBIT Next 5YN/A
FCF growth 1Y-67.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.24%
OCF growth 3YN/A
OCF growth 5YN/A